Company Filing History:
Years Active: 2017-2018
Title: **Inventor Spotlight: Chulho Park**
Introduction
Chulho Park, an innovative inventor based in San Diego, CA, has made significant contributions to the field of biomedicine. With two registered patents to his name, Park's work focuses on advancing therapeutic monitoring and treatment optimization for paclitaxel, a widely used chemotherapy drug.
Latest Patents
Chulho Park's latest patents include:
1. **Antibody-based affinity reagents for binding paclitaxel**: This patent outlines optimized affinity reagent compositions, including antibodies, antibody fragments, and derivatives specifically designed for binding paclitaxel. The invention details the use of complementary determining regions (CDRs) derived from anti-paclitaxel antibodies 8A10 and 3C6, making it instrumental for detecting paclitaxel in samples and determining appropriate dosing for patients.
2. **Methods, devices, and reagents for monitoring paclitaxel concentration in plasma for pharmacokinetic-guided dosing**: This patent describes methods, devices, and compositions aimed at assaying paclitaxel to provide guided therapy for drug monitoring. The technology is essential for improving the therapeutic outcomes of patients undergoing treatment with paclitaxel.
Career Highlights
Chulho Park is currently employed at Autotelic, LLC, where he applies his expertise to develop innovative solutions tailored to enhancing therapeutic efficacy. His work at Autotelic centers around leveraging advanced biotechnological approaches to refine patient care standards within the healthcare sector.
Collaborations
Throughout his career, Park has collaborated with talented colleagues such as Yueh Jung Lee and Vuong Trieu. These collaborations highlight a collective effort towards the advancement of cutting-edge therapeutic applications, reinforcing the importance of teamwork in the realm of innovation.
Conclusion
Chulho Park exemplifies the spirit of innovation through his inventive work and collaborative initiatives in the biomedicine field. As he continues to make strides with his cutting-edge patents, Park's contributions are poised to enhance therapeutic monitoring and optimize treatment outcomes for patients receiving paclitaxel therapy.